Interferon lambda for COVID-19

 Interferon lambda has been reported as potentially beneficial for COVID-19 in the following study.
COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 210+ treatments. We have not reviewed interferon lambda in detail.
Shokri-Afra et al., Targeting SIRT1: A Potential Strategy for Combating Severe COVID‐19, BioMed Research International, doi:10.1155/bmri/9507417
Sirtuin 1 (SIRT1) is a crucial regulator of cellular processes, including inflammation, metabolism, and stress responses, playing a significant role in the body′s defense mechanisms. During SARS‐CoV‐2 infection, SIRT1 plays a crucial role in modulating the immune response. This protein helps to enhance the antiviral response through deacetylating key transcription factors and regulating proinflammatory cytokines, thereby reducing the cytokine storm (an overwhelming immune response) associated with severe COVID‐19 cases. SIRT1 influences the expression of angiotensin‐converting enzyme 2 (ACE2), the primary receptor for SARS‐CoV‐2, thereby potentially mitigating viral entry and replication. Natural activators of SIRT1, such as resveratrol, have been shown to enhance its activity, offering promising avenues for therapeutic interventions aimed at bolstering the immune response during COVID‐19. Understanding the multifaceted role of SIRT1 in human defense mechanisms against SARS‐CoV‐2 could pave the way for innovative strategies to manage COVID‐19 and similar viral infections, emphasizing the importance of SIRT1 as a potential target for future therapeutic approaches.